Overview

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Status:
Recruiting

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor/axillary lymph nodes) who did not achieve pCR after neoadjuvant therapy

Phase:

Phase 2

Details

Lead Sponsor:

Fujian Medical University Union Hospital

Treatments:

Capecitabine
Pertuzumab
Trastuzumab